HCG in TRT — preserving fertility on testosterone

This is not a rare story. And the biology behind it is worth understanding in full, because the same biology that explains the problem also explains how HCG addresses it.

Testosterone replacement works by introducing exogenous testosterone — testosterone from outside the body — into the bloodstream. The hypothalamus, the small brain structure that orchestrates the entire hormonal axis, constantly monitors circulating testosterone levels. When levels are adequate, the hypothalamus reduces its output of GnRH, the signal that tells the pituitary to release LH and FSH. When exogenous testosterone is high and consistent, the hypothalamus reads those levels and concludes that the testes are already working overtime. GnRH drops. The pituitary responds to that drop by reducing LH output — often to near zero. And LH is the signal the testes require to do most of what they do.

LH — luteinizing hormone — acts on Leydig cells, the specialized cells within the testes responsible for testosterone synthesis. Without LH stimulation, the Leydig cells go dormant. Testicular testosterone production stops. This might seem redundant when you're getting testosterone from an injection or a gel, but it isn't — because the testosterone the testes produce when properly stimulated reaches concentrations inside the testes roughly a thousand times higher than serum levels. That intratesticular testosterone concentration is not just a quirk of anatomy. It's a physiological requirement for spermatogenesis. The Sertoli cells that support sperm development depend on it. Without it, sperm production slows, then stops.

The physical evidence of this process is visible. The testes atrophy — they shrink, noticeably, over months of TRT without LH stimulation. Some men notice this themselves. Some don't, until a provider points it out. The shrinkage reflects the dormancy of the Leydig cells, the reduction in fluid and cellular activity that comes from a structure that's essentially been turned off. It's not dramatic in most cases, not painful, and in most cases reversible — but it is real, and it matters beyond appearance.

Here is where HCG enters the picture.

Human chorionic gonadotropin is a naturally occurring hormone produced by the placenta during pregnancy. Its physiological role in that context is to maintain the corpus luteum — the temporary endocrine structure that produces progesterone and keeps a pregnancy viable in early gestation, before the placenta takes over that function. The way it does this is by mimicking LH. HCG's molecular structure includes the same alpha subunit that LH uses, with a different beta subunit, and the LH receptor on the Leydig cell cannot reliably distinguish between them. HCG binds the LH receptor with high affinity — in some respects higher affinity than LH itself — and the Leydig cell responds by resuming testosterone synthesis.

This is the therapeutic exploit. If you can deliver an LH signal to the testes while the pituitary's own LH output is suppressed by exogenous testosterone, you can preserve testicular function — intratesticular testosterone, spermatogenesis, and testicular volume — despite being on TRT. The pituitary is suppressed, but the Leydig cell doesn't know or care where the LH signal is coming from. HCG gets there through a different route and the cell responds the same way.

The protocols that have emerged in clinical practice for TRT with concurrent HCG typically involve subcutaneous injections of 250 to 500 IU two to three times per week. The lower end of that range is often sufficient to maintain testicular function and prevent atrophy. Higher doses can produce more robust stimulation but also increase the risk of excess estradiol production, since Leydig cell activation drives aromatization — conversion of testosterone to estrogen — as a secondary effect. This is something a prescribing provider monitors with labs, and it's one of the reasons the dosing conversation is individual rather than universal.

What the research shows, and what clinical practice has largely confirmed, is that men who use HCG concurrently with TRT maintain significantly better semen parameters than those on TRT alone. Sperm counts, motility, and morphology are all better preserved. Testicular volume is maintained more reliably. For men who want to keep the option of conception open, or who are actively trying to conceive while remaining on TRT, concurrent HCG has become standard practice in the hands of providers who approach fertility as part of the treatment plan rather than an afterthought. Beyond fertility, maintaining that LH-like signal through TRT may also support libido and mood in ways serum testosterone alone doesn't fully predict, and it can ease the transition if a man later chooses to come off testosterone. The larger point is that fertility on TRT is not an all-or-nothing trade-off but a question of how the protocol is built — which is exactly why it belongs in an upfront conversation with a prescribing provider who monitors labs and individualizes the dose, rather than a realization that arrives eighteen months in.